J T Callaghan

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. ncbi Olanzapine. Pharmacokinetic and pharmacodynamic profile
    J T Callaghan
    Lilly Laboratory for Clinical Research, Indiana University Hospital, Indianapolis, USA
    Clin Pharmacokinet 37:177-93. 1999
  2. ncbi Absorption studies of the H2-blocker nizatidine
    M P Knadler
    Lilly Research Laboratories, Lilly Laboratory for Clinical Research, Indianapolis, IN
    Clin Pharmacol Ther 42:514-20. 1987
  3. ncbi QT effects of duloxetine at supratherapeutic doses: a placebo and positive controlled study
    Lu Zhang
    Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, USA
    J Cardiovasc Pharmacol 49:146-53. 2007
  4. ncbi The effects of supratherapeutic doses of duloxetine on blood pressure and pulse rate
    Michael A Derby
    Eli Lilly and Company, Indianapolis, IN, USA
    J Cardiovasc Pharmacol 49:384-93. 2007

Collaborators

  • Lu Zhang
  • Michael A Derby
  • Celedon R Gonzales
  • Malcolm I Mitchell
  • Philip T Leese
  • Jill C Chappell
  • David Hoelscher
  • Larry Ereshefsky
  • Mark Leibowitz
  • M P Knadler
  • A Rubin
  • B D Obermeyer
  • R F Bergstrom

Detail Information

Publications4

  1. ncbi Olanzapine. Pharmacokinetic and pharmacodynamic profile
    J T Callaghan
    Lilly Laboratory for Clinical Research, Indiana University Hospital, Indianapolis, USA
    Clin Pharmacokinet 37:177-93. 1999
    ..However, dosage modification should be considered for patients characterised by a combination of factors associated with decreased oxidative metabolism, for example, debilitated or elderly women who are nonsmokers...
  2. ncbi Absorption studies of the H2-blocker nizatidine
    M P Knadler
    Lilly Research Laboratories, Lilly Laboratory for Clinical Research, Indianapolis, IN
    Clin Pharmacol Ther 42:514-20. 1987
    ..Gelusil reduced the amount of nizatidine absorbed by about 10%, charcoal reduced it by about 30%, and propantheline did not affect it...
  3. ncbi QT effects of duloxetine at supratherapeutic doses: a placebo and positive controlled study
    Lu Zhang
    Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, USA
    J Cardiovasc Pharmacol 49:146-53. 2007
    ..The electrophysiological effects of duloxetine at supratherapeutic exposures were evaluated to ensure compliance with regulatory criteria and to assess the QT prolongation potential...
  4. ncbi The effects of supratherapeutic doses of duloxetine on blood pressure and pulse rate
    Michael A Derby
    Eli Lilly and Company, Indianapolis, IN, USA
    J Cardiovasc Pharmacol 49:384-93. 2007
    ..Overall, the types of adverse events reported in this study were similar to those in other studies of duloxetine in healthy subjects...